RxDoctor Payments Data

Eric Castleman, MD

Cardiovascular Disease · Torrance, CANPI 1760491344

Payments from drug & device makers

$6,690in general payments, 2019–2025

Across 372 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$935
  • Novartis$877
  • Pfizer$656
  • Johnson & Johnson$641
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$396
  • E.r. Squibb & Sons, L.L.C.$372
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,65699%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,690 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$261,255
Medicare patients
2,345
Services billed
5,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban482$579,689
XareltoRivaroxaban143$170,231
EntrestoSacubitril/Valsartan112$136,702
BrilintaTicagrelor88$79,380
Repatha SureclickEvolocumab41$26,742
Repatha SyringeEvolocumab18$10,870
Praluent PenAlirocumab15$9,154
ClopidogrelClopidogrel Bisulfate528$6,849
Atorvastatin Calcium507$6,292
Metoprolol Succinate437$6,039
Dabigatran EtexilateDabigatran Etexilate Mesylate14$5,246
Prasugrel Hcl31$3,765
Losartan Potassium287$3,520
Ezetimibe116$2,458
Rosuvastatin Calcium180$2,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$656$579,689482 claims
Johnson & JohnsonXarelto$641$170,231143 claims
NovartisEntresto$877$136,702112 claims
AstraZenecaBrilinta$282$79,38088 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →